All In Biotech

NDA 020148 · Bausch

Migranal

Dihydroergotamine Mesylate · Nasal

Last checked: Nov 19, 2026Latest source record: May 9, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Dec 8, 1997

Approved uses

1

Original approval plus efficacy supplements

Registered trials

18

5 Phase 3, 0 recruiting

FAERS reports

829

652 serious, 21 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: PERIPHERAL ISCHEMIA FOLLOWING COADMINISTRATION WITH POTENT CYP3A4 INHIBITORS Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of DIHYDROERGOTAMINE with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP 3A4 inhibition elevates the serum levels of DIHYDROERGOTAMINE, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of these medications is contraindicated. (see CONTRAINDICATIONS and WARNINGS ).

What it is approved for

From the label in effect Mar 6, 2025.

INDICATIONS AND USAGE Dihydroergotamine Mesylate Nasal Spray is indicated for the acute treatment of migraine headaches with or without aura. Dihydroergotamine Mesylate Nasal Spray is not intended for the prophylactic therapy of migraine or for the management of hemiplegic or basilar migraine.

Mechanism: Mechanism of Action Dihydroergotamine binds with high affinity to 5-HT 1Dα and 5-HT 1Dβ receptors. It also binds with high affinity to serotonin 5-HT 1A , 5-HT 2A , and 5-HT 2C receptors, noradrenaline α 2A , α 2B and α 1 receptors, and dopamine D 2L and D 3 receptors. The therapeutic activity of dihydroergotamine in migraine is generally attributed to the agonist effect at 5-HT 1D receptors. Two current theories have been proposed to explain the efficacy of 5-HT 1D receptor agonists in migraine. One theory suggests that activation of 5-HT 1D receptors located on intracranial blood vessels,...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 8, 1997 Original approval · Type 3 - New Dosage Form Review
1 products under this application
  • MIGRANAL · DIHYDROERGOTAMINE MESYLATE 0.5MG/SPRAY · SPRAY, METERED, NASAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Dihydroergotamine" as an intervention, any sponsor and status, largest first.

All 18 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective387
  • off label use359
  • hyperhidrosis356
  • nightmare339
  • sedation339
  • nausea338
  • product use in unapproved indication293
  • nephrolithiasis252
  • migraine79
  • treatment failure57
  • dyspnoea52
  • abdominal pain47

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200417
200516
200624
200724
200820
200915
201018
201126
201226
20132
20142
20152
20169
201718
201814
201926
202018
202164
202270
202350
2024125
202584
2026159

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Migranal (Dihydroergotamine Mesylate)

2024 spending

$925K

Beneficiaries

48

236 claims

Per beneficiary

$19,264

$442.42 per unit

View as table
YearSpending
2020$1,297,561
2021$608,440
2022$486,180
2023$552,398
2024$924,650

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 247 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.